Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Raffeld

Showing results (171-180 of 276) with videos related to

Pageof 28
Sort By:
Blood|November 8, 2018
<i>CREBBP</i> gene mutations are frequently detected in in situ follicular neoplasiaJanine Schmidt, Joan Enric Ramis-Zaldivar, Irina Bonzheim, et al.
Acta Neuropathologica Communications|July 10, 2020
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaMark Raffeld, Zied Abdullaev, Svetlana D Pack, et al.
Acta Neuropathologica|January 24, 2024
Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomasLara C Pohl, Maximilian Leitheiser, Denise Obrecht, et al.
The American Journal of Surgical Pathology|September 16, 2016
EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic FeaturesAlina Nicolae, Karthik A Ganapathi, Trinh Hoc-Tran Pham, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood|October 8, 2025
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemiaBrett Schroeder, Constance M Yuan, Hao-Wei Wang, et al.
Blood|March 1, 2003
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyRichard F Little, Stefania Pittaluga, Nicole Grant, et al.
Frontiers in Immunology|January 9, 2019
A Unique Heterozygous <i>CARD11</i> Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation FamilyMarylin Desjardins, Swadhinya Arjunaraja, Jeffrey R Stinson, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2014
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disordersFanny Legrand, Nenad Tomasevic, Olga Simakova, et al.
Haematologica|August 24, 2019
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroupsCaoimhe Egan, Alina Nicolae, Justin Lack, et al.
Pageof 28

Showing results (171-180 of 276) with videos related to

Sort By:
Pageof 28
Blood|November 8, 2018
<i>CREBBP</i> gene mutations are frequently detected in in situ follicular neoplasiaJanine Schmidt, Joan Enric Ramis-Zaldivar, Irina Bonzheim, et al.
Acta Neuropathologica Communications|July 10, 2020
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaMark Raffeld, Zied Abdullaev, Svetlana D Pack, et al.
Acta Neuropathologica|January 24, 2024
Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomasLara C Pohl, Maximilian Leitheiser, Denise Obrecht, et al.
The American Journal of Surgical Pathology|September 16, 2016
EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic FeaturesAlina Nicolae, Karthik A Ganapathi, Trinh Hoc-Tran Pham, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood|October 8, 2025
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemiaBrett Schroeder, Constance M Yuan, Hao-Wei Wang, et al.
Blood|March 1, 2003
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyRichard F Little, Stefania Pittaluga, Nicole Grant, et al.
Frontiers in Immunology|January 9, 2019
A Unique Heterozygous <i>CARD11</i> Mutation Combines Pathogenic Features of Both Gain- and Loss-of-Function Patients in a Four-Generation FamilyMarylin Desjardins, Swadhinya Arjunaraja, Jeffrey R Stinson, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2014
The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disordersFanny Legrand, Nenad Tomasevic, Olga Simakova, et al.
Haematologica|August 24, 2019
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroupsCaoimhe Egan, Alina Nicolae, Justin Lack, et al.
Pageof 28